JNJ - Axsome Therapeutics: Sizable Sales Upside From A Promising Trial Demands A Premium
Investment Thesis
Backed by positive results from a phase 02 trial for Major Depressive Disorder ((MDD)), the shares of Axsome Therapeutics, Inc. (AXSM) have jumped nearly seven times in 2019 so far. Out of the six clinical trials currently in progress, four data readouts will be available before the year-end. Favorable results could support two separate NDA (New Drug Application) filings in 2020 to treat MDD and migraine. With its novel mechanism of action and two separate pathways available for an FDA (U.S. Food and Drug Administration) approval, the drug. AXS-05 holds particular